TEVA-ESCITALOPRAM TABLET

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

ESCITALOPRAM (ESCITALOPRAM OXALATE)

Inapatikana kutoka:

TEVA CANADA LIMITED

ATC kanuni:

N06AB10

INN (Jina la Kimataifa):

ESCITALOPRAM

Kipimo:

10MG

Dawa fomu:

TABLET

Tungo:

ESCITALOPRAM (ESCITALOPRAM OXALATE) 10MG

Njia ya uendeshaji:

ORAL

Vitengo katika mfuko:

30/100

Dawa ya aina:

Prescription

Eneo la matibabu:

SELECTIVE-SEROTONIN REUPTAKE INHIBITORS

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0150435002; AHFS:

Idhini hali ya:

APPROVED

Idhini ya tarehe:

2014-09-10

Tabia za bidhaa

TEVA-ESCITALOPRAM (Escitalopram Oxalate Tablets) Page 1 of 63
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
TEVA-ESCITALOPRAM
Escitalopram Oxalate Tablets
Tablets, 10 mg and 20 mg escitalopram (as escitalopram oxalate), Oral
Teva Standard
Antidepressant
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
M1B 2K9
Canada
www.tevacanada.com
Date of Initial Authorization:
September 10, 2014
Date of Revision:
August 16, 2022
Submission Control Number: 264520
TEVA-ESCITALOPRAM (Escitalopram Oxalate Tablets) Page 2 of 63
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, Hematologic
08/2022
7 WARNINGS AND PRECAUTIONS, Reproductive Health: Female and
Male Potential
08/2022
7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant Women
08/2022
TABLE OF CONTENTS
Sections or subsections that are not applicable at the time of
authorization are not listed.
RECENT MAJOR LABEL CHANGES
.......................................................................................
2
TABLE OF CONTENTS
.........................................................................................................
2
PART I:
HEALTH PROFESSIONAL INFORMATION
............................................................ 4
1
INDICATIONS
.........................................................................................................
4
1.1
Pediatrics
.............................................................................................................
4
1.2
Geriatrics
.............................................................................................................
4
2
CONTRAINDICATIONS
............................................................................................
4
4
DOSAGE AND ADMINISTRATION
............................................................................
5
4.1
Dosing Considerations
.........................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
................................................... 6
4.4
Administration
....